Niki BioSolutions, Inc. (NIKI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Niki BioSolutions, Inc. (NIKI) has a cash flow conversion efficiency ratio of -0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-535.25K) by net assets ($13.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Niki BioSolutions, Inc. stock valuation for the company's overall valuation and market capitalisation.
Niki BioSolutions, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Niki BioSolutions, Inc. stock price for real-time trading data and today's change.
Niki BioSolutions, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niki BioSolutions, Inc. ranked by their cash flow conversion efficiency. Review NIKI free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
iSpecimen Inc
NASDAQ:ISPC
|
-0.397x |
|
Interbud-Lublin SA
WAR:ITB
|
-0.383x |
|
Chakana Copper Corp
V:PERU
|
-0.248x |
|
Montero Mining and Exploration Ltd
V:MON
|
-0.134x |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
-0.187x |
|
Enova Mining Ltd
AU:ENV
|
-0.031x |
|
S&U plc
LSE:SUS
|
-0.193x |
|
Love Group Global Ltd
AU:LVE
|
0.677x |
Annual Cash Flow Conversion Efficiency for Niki BioSolutions, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Niki BioSolutions, Inc. from 2017 to 2025. Also see how large is Niki BioSolutions, Inc.'s balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.79 Million | $-1.84 Million | -0.133x | -31.82% |
| 2024-12-31 | $11.78 Million | $-1.19 Million | -0.101x | +79.88% |
| 2023-12-31 | $15.38 Million | $-7.72 Million | -0.502x | +68.07% |
| 2022-12-31 | $7.83 Million | $-12.32 Million | -1.573x | -87.90% |
| 2021-12-31 | $17.51 Million | $-14.65 Million | -0.837x | -100.42% |
| 2020-12-31 | $38.15 Million | $-15.93 Million | -0.418x | +53.66% |
| 2019-12-31 | $14.85 Million | $-13.38 Million | -0.901x | -194.02% |
| 2018-12-31 | $32.75 Million | $-10.04 Million | -0.306x | -60.21% |
| 2017-12-31 | $30.23 Million | $-5.78 Million | -0.191x | -- |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more